Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Apollomics Inc. Warrant (APLMW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/10/2025: APLMW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 122.66M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.03 - 0.03 | Updated Date 06/28/2025 |
52 Weeks Range 0.03 - 0.03 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20542439 | Price to Sales(TTM) - |
Enterprise Value 20542439 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.12 | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Apollomics Inc. Warrant
Company Overview
History and Background
Apollomics Inc. Warrant is associated with Apollomics Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies. The company was founded in 2014. Key milestones include the advancement of its lead drug candidates into clinical trials.
Core Business Areas
- Oncology Drug Development: Apollomics Inc. is primarily focused on developing innovative therapies for cancer. This includes a pipeline of novel antibodies and antibody-drug conjugates (ADCs) targeting various cancer types.
Leadership and Structure
Information on the specific leadership team and organizational structure for Apollomics Inc. Warrant is not readily available as it represents a derivative financial instrument. The leadership and structure would pertain to the parent company, Apollomics Inc.
Top Products and Market Share
Key Offerings
- Product Name 1: Apol505 (anti-PD-1 antibody): Description: A novel antibody designed to block the PD-1 pathway, a key mechanism by which cancer cells evade the immune system. Market Share Data: Not applicable as it is an investigational drug. Number of Users/Revenue: Not applicable. Competitors: Pembrolizumab (Keytruda by Merck), Nivolumab (Opdivo by Bristol Myers Squibb), Cemiplimab (Libtayo by Regeneron).
- Product Name 2: Apol101 (anti-HER3 antibody-drug conjugate): Description: An ADC targeting the HER3 receptor, which is overexpressed in several solid tumors. Market Share Data: Not applicable as it is an investigational drug. Number of Users/Revenue: Not applicable. Competitors: Trastuzumab deruxtecan (Enhertu by Daiichi Sankyo and AstraZeneca).
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in oncology, is characterized by rapid innovation, significant R&D investment, and a highly competitive landscape. The immunotherapy segment is experiencing substantial growth due to its potential to offer durable responses in various cancers.
Positioning
Apollomics Inc. is positioned as an emerging player in the oncology immunotherapy space, seeking to differentiate itself through novel drug candidates with potentially improved efficacy or safety profiles. Its focus on specific targets like PD-1 and HER3 aims to address unmet needs in cancer treatment.
Total Addressable Market (TAM)
The TAM for oncology treatments, and specifically immunotherapies, is vast and growing, estimated to be in the hundreds of billions of dollars globally. Apollomics Inc.'s position is that of a niche player within this large market, aiming to capture a segment through its specialized pipeline. Its success is contingent on successful clinical development and market penetration of its drug candidates.
Upturn SWOT Analysis
Strengths
- Innovative pipeline of novel immuno-oncology drug candidates.
- Targeting well-validated pathways with potential for broad application.
- Experienced scientific and management team.
Weaknesses
- Clinical-stage company with no approved products, thus no current revenue generation from product sales.
- High reliance on successful clinical trials and regulatory approvals.
- Significant funding requirements for R&D and clinical development.
- Limited brand recognition compared to established biopharmaceutical companies.
Opportunities
- Growing market for cancer immunotherapies.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
- Advancements in biotechnology and drug delivery technologies.
- Addressing unmet needs in specific cancer indications.
Threats
- High failure rates in clinical drug development.
- Intense competition from established and emerging biopharmaceutical companies.
- Evolving regulatory landscape for drug approvals.
- Pricing pressures and reimbursement challenges for new therapies.
- Economic downturns affecting investment in biotech.
Competitors and Market Share
Key Competitors
- Merck & Co., Inc. (MRK)
- Bristol Myers Squibb Company (BMY)
- Regeneron Pharmaceuticals, Inc. (REGN)
- Daiichi Sankyo Company, Limited (DSNKY)
- AstraZeneca PLC (AZN)
Competitive Landscape
Apollomics Inc. faces a highly competitive landscape dominated by large pharmaceutical companies with extensive R&D resources and established market presence. Apollomics' advantage lies in its potentially novel mechanisms of action and targeted therapies, aiming to carve out specific niches. Its disadvantages include limited financial resources and the significant risk associated with clinical development compared to established players.
Growth Trajectory and Initiatives
Historical Growth: Growth for Apollomics Inc. would be measured by its progress in advancing its drug pipeline through preclinical and clinical stages, securing intellectual property, and achieving regulatory milestones.
Future Projections: Future projections are speculative and depend heavily on the successful clinical development and potential commercialization of its drug candidates. Analyst estimates would focus on potential peak sales of future drugs and the probability of success in clinical trials.
Recent Initiatives: Recent initiatives would likely include the initiation or progression of clinical trials for its lead drug candidates, potential corporate partnerships, and fundraising activities to support its development programs.
Summary
Apollomics Inc. Warrant represents a speculative investment tied to the development of novel cancer immunotherapies. The company's strength lies in its innovative pipeline and targeting of key cancer pathways. However, it faces significant weaknesses due to its clinical-stage status and high R&D costs. Opportunities exist in the growing immunotherapy market, but threats from clinical trial failures and intense competition are considerable. Continued progress in clinical trials and successful fundraising are crucial for its future.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases and investor relations materials (for Apollomics Inc.)
- Financial news outlets
- Biopharmaceutical industry research reports
- Clinical trial databases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial or investment advice. The performance of warrants is highly speculative and carries substantial risk of loss. Data regarding market share and financial metrics for Apollomics Inc. are based on the parent company and may not directly reflect the warrant's value. Information regarding Apollomics Inc. Warrant is limited due to its nature as a derivative.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apollomics Inc. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-26 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website |
Full time employees 59 | Website | ||
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.